Clinical Pharmacology Consultant
Entrada Therapeutics
Clinical Pharmacology Consultant
Entrada Therapeutics
Develops intracellular therapeutics using endosomal escape
What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1).
2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670).
We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families.
We are seeking a dynamic Clinical Pharmacology Consultant who will bring extensive expertise in clinical pharmacology to our clinical stage programs. The ideal candidate will have a strong background in study design within the biotechnology or pharmaceutical industry and be passionate about translating science into approved and accessible medicines. You will report directly to the Head of Clinical Pharmacology and partner closely with various functions of our growing organization.
At Entrada, our passion for science, our devotion to patients and our values drives our behavior:
To thrive on our team, you will need to come with:
This is a US based remote contract position, looking for support from 30 – 40 hours per week #LI-Remote #LI-JF1
Entrada Therapeutics is an equal opportunity employer. Qualified candidates will receive consideration for employment without regard to race, color, religion, national origin, gender, sexual orientation, gender identity or expression, age, mental or physical disability, and genetic information, marital status, citizenship status, military status, protected veteran status or any other category protected by law.
Entrada does not accept unsolicited resumes from any source other than directly from candidates. For the protection of all parties involved in the recruiting process, resumes will only be accepted from recruiters/agencies if a signed agreement is in place at the inception of the recruiting effort and authorized for a specified position. Unsolicited resumes sent to Entrada from recruiters/agencies do not constitute any type of relationship between the recruiter/agency and Entrada and do not obligate Entrada to pay fees if we hire from those resumes.
Entrada Therapeutics, Inc. (the “Entrada,” “we,” “us,” or “our”) respects your privacy and we want you to be familiar with how we collect, use, share, or otherwise process, your Personal Information. Please reference our privacy statement here to understand how and when your data is being used.
Develops intracellular therapeutics using endosomal escape
Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.
Explore more opportunities at Entrada Therapeutics